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Abstract A number of elongation factor-2 kinase (eEF-2K)
mutants were constructed to investigate features of this kinase
that may be important in its activity. Typical protein kinases
possess a highly conserved lysine residue in subdomain II which
follows the GXGXXG motif of subdomain I. Mutation of two
lysine residues, K340 and K346, which follow the GXGXXG
motif in eEF-2K had no effect on activity, showing that such a
lysine residue is not important in eEF-2K activity. Mutation of a
conserved pair of cysteine residues C-terminal to the GXGXXG
sequence, however, completely inactivated eEF-2K. The eEF-2K
CaM binding domain was localised to residues 77^99 which
reside N-terminal to the catalytic domain. Tryptophan 84 is an
important residue within this domain as mutation of this residue
completely abolishes CaM binding and eEF-2K activity.
Removal of approximately 130 residues from the C-terminus of
eEF-2K completely abolished autokinase activity; however,
removal of only 19 residues inhibited eEF-2 kinase activity but
not autokinase activity, suggesting that a short region at the C-
terminal end may be important in interacting with eEF-2.
Likewise, removal of between 75 and 100 residues from the
N-terminal end completely abolished eEF-2K activity.
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1. Introduction
Calcium regulates a broad range of cellular processes in-
cluding muscle contraction, glycogen metabolism, neurotrans-
mitter release and cell proliferation [1]. Many of the e¡ects of
calcium are mediated by protein phosphorylation via activa-
tion of members of a family of Ca2/calmodulin-dependent
serine/threonine protein kinases (CaMKs). These kinases in-
clude myosin light chain kinase, phosphorylase kinase, CaM
kinases I, II and IV and a Ca2/CaM-dependent kinase which
phosphorylates and activates CaM kinases I and IV [2^4]. The
other CaM kinase is elongation factor-2 kinase (eEF-2K)
which phosphorylates and inactivates eEF-2 [5^9]. eEF-2 me-
diates peptidyl-tRNA translocation from the A- to the P-site
in eukaryotic ribosomes and phosphorylation and inhibition
of eEF-2 leads to the inhibition of mRNA translation [10].
A number of CaMKs share many structural and regulatory
features, possessing a highly conserved catalytic domain fol-
lowed by a calmodulin binding domain. They are also thought
to be autoinhibited by binding of pseudosubstrate sequences
to the active site in the absence of Ca2/CaM [2,11^13]. Re-
cently the determination of the crystal structure of CaMK I
[14] and mutation studies [15] have revealed the involvement
of a number of speci¢c residues in the autoinhibition of this
kinase.
Although eEF-2K is Ca2/CaM-dependent, it is unrelated
to the other CaMKs in terms of amino acid sequence and
appears to represent a distinct family of protein kinases [16^
18]. The only other characterised kinase that displays any
homology to eEF-2K is Dictyostelium myosin heavy chain
kinase (MHCK) which is not a Ca2/CaM-dependent kinase.
The catalytic domain of MHCK possesses about 40% homol-
ogy with a region in rat eEF-2K encompassing residues ap-
proximately 130^320, which presumably represents the eEF-
2K catalytic domain [19,20].
In this paper we have used mutagenesis to investigate the
structural organisation of eEF-2K and to de¢ne residues
which may be important in the catalytic activity of eEF-2K.
2. Materials and methods
2.1. Materials
Biotinylated CaM was prepared in the presence of 1 mM calcium as
described [21] using 1.2 mg of bovine brain CaM (Sigma). eEF-2 was
puri¢ed from rabbit reticulocytes as previously described [22]. pfu
polymerase was from Stratagene. Fugene 6 was purchased from
Boehringer. Anti-myc (9E10) antibody was from Sigma. An antibody
against the N-terminal region of rat eEF-2K was raised in rabbits by
immunisation with GST-eEF-2K 1^99.
2.2. Binding of eEF-2K to biotinylated CaM
eEF-2K in Dulbecco’s PBS (D-PBS) was dot-blotted onto nitro-
cellulose. The membrane was incubated with 12.5 Wg/ml of biotin-
ylated CaM for 1 h. Binding of biotinylated CaM was detected by
subsequent incubation with Extravidin-peroxidase (Sigma) and visual-
isation by ECL. All incubations and washes were done in D-PBS to
ensure CaM remained bound. 1 mM calcium was also added to the
ECL reagents. When required, 5 mM EGTA was added to D-PBS to
chelate free calcium.
2.3. Expression of GST-eEF-2K
PCR was used to amplify cDNA encoding the ¢rst 99 residues of
rat muscle eEF-2K [16] and to introduce a BamHI site before the
initiation codon using the sense primer 5P-TAGCTGGATCCC-
CATGGCAGACGAAGACC-3P and an antisense primer with an
EcoRI site, 3P-CCTCCAGATGGAATTCAGCCC-5P. The cDNA
fragment was ligated into BamHI/EcoRI-digested pGEX-5X-1 fol-
lowed by ligation of an EcoRI fragment encoding the remainder of
eEF-2K to generate pGEX-eEF-2K encoding full-length eEF-2K (1^
724). GST-eEF-2K was expressed in BL21(DE3) cells by induction
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with 0.2 mM IPTG for 4^5 h at ambient temperature. After puri¢ca-
tion using glutathione-agarose, about 1 mg of GST-eEF-2K was ob-
tained per litre of bacterial culture. The full-length GST-eEF-2K had
an apparent molecular weight of approximately 130 kDa as judged by
SDS-PAGE.
Site-directed mutagenesis was carried out using a two-PCR method
[23]. The second PCR was used to amplify the region of eEF-2K
between the unique BsaBI and KpnI restriction sites within eEF-2K.
The cDNAs were sequenced to verify mutagenesis using the T7 Se-
quenase kit (Amersham).
2.4. Transient transfections and eEF-2K assay
eEF-2K with an N-terminal myc-epitope tag (EQKLISEEDL) in-
serted after the N-terminal methionine was constructed using PCR
and was inserted into pcDNA.3.1 (Invitrogen). HEK 293 or CHO.T
cells were transiently transfected with 3 Wg of DNA using Fugene 6 in
6-cm plates. Transfected cells were left for 2 days before serum star-
vation overnight and then lysed in bu¡er as described [24]. Myc-eEF-
2K from 5 Wg of cell protein was immunoprecipitated with anti-myc
antibody (2 Wg coupled to protein G Sepharose) before measurement
of eEF-2K activity as described [24]. Activity of GST-eEF-2K was
assayed by incubation of 0.1 Wg of the kinase with 1 Wg of eEF-2 for
5 min before SDS-PAGE and autoradiography.
3. Results and discussion
Conventional protein kinases possess 11 catalytic subdo-
mains that contain a number of highly conserved residues
[25]. In subdomain I, which is at the N-terminal end of the
catalytic domain, a GXGXXG motif is present which is fol-
lowed by a conserved lysine residue in subdomain II. The
original cloning of cDNA encoding rat eEF-2K [16] revealed
that it had very little homology to conventional protein ki-
nases. However, since eEF-2K also possessed a GXGXXG
sequence, it was thought that the region containing this motif
constituted the N-terminal end of the eEF-2K catalytic do-
main. It was therefore postulated that the ¢rst lysine residue
C-terminal to the GXGXXG sequence (K340) was the invar-
iant lysine in subdomain II. Mutation of this invariant lysine
inactivates most protein kinases. We therefore mutated this
residue to determine whether it was important in the catalytic
activity of eEF-2K. Fig. 1 shows that myc-eEF-2K K340R
expressed in HEK 293 cells was as active as wild-type myc-
eEF-2K. We also mutated the next lysine residue in the se-
quence (K346) to rule out the possibility that this residue was
important. However, again substitution of this residue was
without e¡ect (not shown).
Subsequent to the publication of the sequence of rat eEF-
2K, the Caenorhabditis elegans eEF-2K sequence was pub-
lished [17] as was the mapping of the Dictyostelium MHCK
catalytic domain [20]. From these data several conclusions can
be drawn: ¢rstly the catalytic domain of rat eEF-2K resides
approximately between residues 123 and 325; it has no ho-
mology with the catalytic domains of conventional protein
kinases; the conserved residues between eEF-2K and
MHCK appear to comprise eight subdomains [18]. Among
the residues conserved between eEF-2K and MHCK are
two cysteine resides (C313 and C317 in rat eEF-2K) which
suggests a possible role in catalysis. A role for cysteine pairs in
the catalytic activity of another atypical kinase (BCR) [26] has
Fig. 1. Activity of eEF-2K mutants. A: HEK 293 cells were trans-
fected with empty vector (lane 1) or myc-eEF-2K WT (lane 2),
C313/317A (lane 3) or K340R (lane 4). After immunoprecipitation
with anti-myc antibody, kinase activity was measured as described
in Section 2. B: Myc-eEF-2K from 5 Wg of cell extract was immu-
noprecipitated with anti-myc followed by SDS-PAGE, Western blot-
ting and immunodetection with eEF-2K antibody. Samples applied
to the lanes were as given in A.
Fig. 2. Autophosphorylation and activity of GST-eEF-2K trunca-
tion mutants. A: Various C-terminal GST-eEF-2K truncation mu-
tants were allowed to autophosphorylate in vitro for 40 min in the
presence or absence of Ca2 as indicated. The ¢gure shows an auto-
radiograph of the gel after SDS-PAGE. B: The activity of various
C-terminal eEF-2K truncation mutants against eEF-2 was assayed
as described. C: Activities of various N-terminal eEF-2K truncation
mutants were assayed as in B.
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been proposed which involves the formation of a phospho-
thiol intermediate with ATP. To test whether these two cys-
teine residues were important in catalytic activity they were
both mutated to alanine residues. When expressed in bacteria
as a GST-fusion protein (not shown) or myc-tagged in eu-
karyotic cells, eEF-2K C331/317 was completely inactive
when tested against eEF-2 (Fig. 1), and in addition could
not autophosphorylate (not shown). This suggests that those
cysteine residues are involved in the catalytic activity of eEF-
2K although these experiments alone cannot rule out the pos-
sibility that mutation of these residues interferes with the
structural organisation of the catalytic domain. However,
these results are similar to the BCR protein kinase in which
deletion of either of two essential cysteine pairs results in
complete inhibition of autokinase activity [26].
In order to try to de¢ne the catalytic domain of eEF-2K we
carried out N- and C-terminal truncation mutagenesis and
determined the eEF-2 kinase and autokinase activity of the
mutants. A 35 kDa fragment from the central region of
MHCK which contained intrinsic kinase activity has been
de¢ned by truncation mutagenesis [20]. However, only limited
truncation of eEF-2K from the C-terminal end of the mole-
cule was found to inhibit eEF-2K activity. It was found that
removal of as few as 19 C-terminal residues completely inhib-
ited eEF-2K activity (Fig. 2). This was not simply due to
disruption of ATP binding as truncation mutants with up to
100 residues removed could still autophosphorylate as well as
the full-length protein (Fig. 2A). Further truncation of about
130 residues from the C-terminus did result in autokinase-
defective eEF-2K (Fig. 2A). This is likely to be due to the
disruption of ATP binding and was not due to the removal of
autophosphorylation sites as all of these lie closer to the N-
terminal end (Diggle et al., manuscript in preparation). Trun-
cation of the N-terminal end of eEF-2K also resulted in its
inactivation. However, deletion of a larger region of 75^100
residues is required to inactivate eEF-2K as GST-eEF-2K 74^
724 was active while GST-eEF-2K 100^724 was inactive (Fig.
2C). It is possible that this is due to disruption of ATP bind-
ing or, as GST-eEF-2K 100^724 lacks the CaM binding do-
main, it is possible that this mutant is not activatable since it
cannot bind CaM (see below).
We next investigated the regions of eEF-2K that are impor-
tant in calmodulin binding. We had previously suggested that
a possible CaM binding domain in eEF-2K was towards the
C-terminal end (residues 593^609) based on the computer
prediction that this region possessed amphipathic K-helical
structure. We determined to identify the CaM binding domain
in GST-eEF-2K by using a ¢lter binding assay to assess the
ability of various truncation mutants of eEF-2K to bind bio-
tinylated CaM [21]. Fig. 3 shows that the eEF-2K CaM bind-
ing domain is within the N-terminal 99 amino acids since,
while GST-eEF-2K 1^99 could bind biotinylated CaM, any
truncation mutant lacking the ¢rst 99 amino acids could not.
Furthermore, the CaM binding domain was shown to be be-
tween residues 77 and 99 from the inability of GST-eEF-2K
1^77 to bind to biotinylated CaM (Fig. 3A).
To further prove that this region does constitute the CaM
binding domain, one of the important hydrophobic residues
(W84) was substituted by an alanine residue. Fig. 3 shows that
GST-eEF-2K W84G was unable to bind biotinylated CaM
and was completely inactive even at CaM concentrations
that saturated wild-type eEF-2K.
Examination of the sequence between residues 77 and 99
suggests that since residue 95 is proline this may represent the
extreme C-terminal end of the CaM binding domain as this
residue would disrupt K-helical structure. The sequence of the
Fig. 3. Binding of calmodulin to eEF-2K truncation mutants. A: 1
Wg of various GST-eEF-2K mutants was vacuum-blotted onto nitro-
cellulose membrane. The membrane was incubated with biotinylated
CaM followed by Extravidin-peroxidase. CaM binding was visual-
ised by ECL. GST alone was used as a negative control. The bind-
ing of CaM was strictly dependent upon the presence of free calci-
um in the incubation bu¡ers (not shown). B: Activity of GST-eEF-
2K W84G. Wild-type GST-eEF-2K and GST-eEF-2K W84G (0.1
Wg) were incubated with eEF-2 (1 Wg) in the presence of various
concentrations of CaM as indicated for 5 min. After PAGE the
dried gels were subjected to autoradiography. C: Alignment of eEF-
2K CaM binding domain with that of other CaM binding proteins.
The conserved hydrophobic residues in the 1-5-8-14 CaM binding
domain are shown in bold. SK = skeletal muscle, MLCK = myosin
light chain kinase; NO = nitric oxide.
Fig. 4. Domain structure of eEF-2K. The relative positions of the
CaM binding domain and the catalytic domain are shown as is the
GXGXXG motif within the catalytic domain.
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domain is therefore likely to be FHFKEAWKHAIE-
KAKHMP, which most closely conforms to the 1-5-8-14
type A CaM binding motif and also contains a number of
basic residues which £ank the hydrophobic residues which is
a feature common to this type of CaM binding domain [27].
However, the sequence in eEF-2K does not entirely conform
to this domain type as it lacks a hydrophobic residue at posi-
tion 14 (the conserved hydrophobic residues are in bold). The
corresponding region in C. elegans eEF-2K is homologous to
the rat eEF-2K sequence (Fig. 3C) with position 14 also lack-
ing a hydrophobic residue. This domain type is shared by a
number of mammalian proteins including calcineurin, myosin
light chain kinase and CaM kinase IV (see Fig. 3C) [27]. Fig.
4 shows a diagrammatic representation of eEF-2K domain
structure.
4. Conclusions
The fact that removal of relatively small regions from either
the N- or C-terminus of GST-eEF-2K results in loss of kinase
activity suggests that the maintenance of an active catalytic
domain requires contacts with other regions of the molecule
outside the catalytic domain. This is in contrast to a number
of conventional protein kinases the catalytic domains of which
can be isolated in an active form. Also the active catalytic
domain of Dictyostelium MHCK, the only other characterised
kinase with homology to eEF-2K, can also be isolated [20]. It
is possible that this intractability is a consequence of improper
folding of truncated forms of eEF-2K in bacteria and another
expression system may be more suitable for the production of
active truncated forms of eEF-2K.
While removal of approximately 130 residues from the C-
terminal end of eEF-2K results in loss of autokinase activity,
removal of only 19 residues results in loss of eEF-2K activity
but not autokinase activity. This suggests that the extreme C-
terminal end is essential for the interaction of eEF-2K with
eEF-2. This region may directly interact with eEF-2 or possi-
bly may be required for the oligomerisation of eEF-2K. How-
ever, as yet there is no evidence that oligomerisation of eEF-
2K is required for its activity. Further work will be required
to determine the requirement for the C-terminal region of
eEF-2K for its activity. It is interesting to note that the inter-
action of p90 ribosomal S6 kinase (rsk) with extracellular
signal-regulated kinase (ERK) is dependent upon a small re-
gion at the C-terminal end of p90 rsk and deletion of the C-
terminal nine residues completely eliminated the interaction of
the two kinases and prevented activation of p90 rsk by ERK
in BHK cells [28].
The positioning of the CaM binding domain immediately
N-terminal to the catalytic domain in eEF-2K highlights a
further distinction between eEF-2K and the other CaMKs
in which the CaM binding domain is C-terminal to the cata-
lytic domain. In CaMK I, CaMK IV and CaMKK the CaM
binding domain is preceded and overlapped by an autoinhi-
bitory domain. It is unclear as yet whether eEF-2K also pos-
sesses such an autoinhibitory domain and whether it is close
to the CaM binding domain.
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